1. Generics Bulletin
  2. >>Business
  3. >>Deals

Mylan And Upjohn Put A Price On $11.5bn Viatris Debt

Delayed Combination Of The Two Firms Is Set For Q4

 
• By Dean Rudge

Upjohn is to pay parent company Pfizer $12bn in cash in order to complete its separation and merger with Mylan to form Viatris, a new company set to be unveiled by the end of this year following a delay caused by the COVID-19 pandemic. Details of the debt financing tapped into the by the company have just been announced.

Calendar with dollar bills. - Illustration
Upjohn has issued $11.5bn in senior notes to complete its separation and merger with Mylan • Source: Shutterstock

Mylan and Pfizer’s Upjohn off-patent and mature brands unit have announced pricing for roughly $11.5bn of senior debt payable to Pfizer for the two businesses to merge into Viatris, a deal hit by setbacks that is now slated for the completion by the end of 2020.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business